Drug Profile


Alternative Names: G154578; GLPG-0778; GSK-2586184; GSK2586184A

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Developer GlaxoSmithKline
  • Class Amides; Azetidines; Cyclopropanes; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Unspecified
  • Discontinued Plaque psoriasis; Systemic lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Nov 2014 Efficacy and adverse events data from a phase IIa trial in Plaque psoriasis released by Galapagos
  • 26 Aug 2014 Discontinued - Phase-I for Ulcerative colitis in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top